Literature DB >> 937880

Intravascular coagulation with use of human prothrombin complex concentrates.

A I Cederbaum, P M Blatt, H R Roberts.   

Abstract

Prothrombin complex concentrates are used in the treatment of the congenital bleeding disorders associated with Factors II, VII, IX, and X deficiencies. They have also been extensively used to treat acquired coagulation abnormalities secondary to vitamin K deficiency, warfarin ingestion, and various types of liver disease. The reported complications of prothrombin complex concentrates administration include hepatitis, anaphylaxis, and thrombosis. This paper documents the development of disseminated intravascular coagulation in association with the administration of prothrombin complex concentrates to patients with liver disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 937880     DOI: 10.7326/0003-4819-84-6-683

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

1.  Assessment of thrombogenicity of activated and non-activated prothrombin concentrates in a rat model.

Authors:  S Silberman; J Fareed; J Walenga
Journal:  Br J Exp Pathol       Date:  1986-08

2.  Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.

Authors:  A Shirahata; T Kamiya; J Takamatsu; T Kojima; K Fukutake; M Arai; H Hanabusa; H Tagami; A Yoshioka; G M Shima; G H Naka; G S Fujita; Y Minamoto; J Kamizono; H Saito
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

3.  Non-mechanical hemorrhage in severe liver injury.

Authors:  G P Clagett; W R Olsen
Journal:  Ann Surg       Date:  1978-04       Impact factor: 12.969

4.  Binding of human factor VII and VIIa to monocytes.

Authors:  G J Broze
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

5.  Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.

Authors:  D P O'Brien; A R Giles; K M Tate; G A Vehar
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

6.  Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.

Authors:  U Hedner; W Kisiel
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.